These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 18672532)

  • 1. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
    Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
    J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance mutations during structured treatment interruptions.
    Yerly S; Fagard C; Günthard HF; Hirschel B; Perrin L;
    Antivir Ther; 2003 Oct; 8(5):411-5. PubMed ID: 14640388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.
    Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P
    Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006.
    Lalezari JP; Ward DJ; Tomkins SA; Garges HP
    J Antimicrob Chemother; 2007 Jul; 60(1):170-4. PubMed ID: 17491001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype.
    Izopet J; Souyris C; Sandres-Sauné K; Puissant B; Obadia M; Pasquier C; Puel J; Blancher A; Massip P
    J Med Virol; 2002 Nov; 68(3):305-10. PubMed ID: 12226815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent antiretroviral therapy in patients with controlled HIV infection.
    Marchou B; Tangre P; Charreau I; Izopet J; Girard PM; May T; Ragnaud JM; Aboulker JP; Molina JM;
    AIDS; 2007 Feb; 21(4):457-66. PubMed ID: 17301564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Niubó J; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2012; 17(3):577-83. PubMed ID: 22301439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.
    Fox Z; Dragsted UB; Gerstoft J; Phillips AN; Kjaer J; Mathiesen L; Youle M; Katlama C; Hill A; Bruun JN; Clumeck N; Dellamonica P; Lundgren JD;
    Antivir Ther; 2006; 11(6):761-70. PubMed ID: 17310820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
    Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
    J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.
    Molina JM; Marcelin AG; Pavie J; Heripret L; De Boever CM; Troccaz M; Leleu G; Calvez V;
    J Infect Dis; 2005 Mar; 191(6):840-7. PubMed ID: 15717257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial comparing regimens of four reverse transcriptase inhibitors given together or cyclically in HIV-1 infection--the Quattro Trial. Quattro Steering Committee.
    AIDS; 1999 Nov; 13(16):2209-17. PubMed ID: 10563706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
    Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
    Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.